Life Science Tools Market Summary
The life science tools market is expected to increase at a compound annual growth rate (CAGR) of 10.21% from 2025 to 2030, from an estimated USD 167.82 billion in 2025 to USD 299.56 billion by 2030. The main drivers of this expansion are the increasing use of genomic technologies, growing investments in pharmaceutical and biotechnology R&D, and the growing need for sophisticated research instruments.
Key Market Trends & Insights
- North America dominated the life science tools industry with the largest revenue share of 44.69% in 2024.
- The life science tools market in the U.S. is the largest in North America, primarily due to its advanced healthcare infrastructure and substantial investment in biomedical research.
- By technology, the cell biology technology segment held the largest revenue share of 33.94% in 2024.
- By product & services, the cell culture systems and 3D cell culture segment held the largest revenue share of 16.48% in 2024.
- By end-use, the healthcare segment held the largest life science market revenue share of 32.01% in 2024
Market Size & Forecast
- 2024 RevenueUSD 167.82 Billion
- 2030 Projected Market SizeUSD 299.56 Billion
- CAGR (2025-2030)10.21%
- North AmericaLargest market in 2024
- Asia-PacificFastest growing market
In addition, advancements in proteomics, growing adoption of personalized medicine, and integrating AI and automation in research processes drive market expansion. Government support and the surge in healthcare needs further contribute to the market’s positive outlook over the forecast period.
AI-Driven Transformation in the Life Science Tools Industry
The life science tools sector is quickly changing because of artificial intelligence (AI), which is becoming a crucial part of research and development processes. Businesses are using AI more and more to improve data processing skills, expedite intricate biological research, and hasten the development of new treatments. The time from discovery to application can be greatly shortened by combining AI with life science technologies to process large datasets produced by proteomics, metabolomics, and genomics platforms more quickly and accurately.
The use of AI in the life science industry is especially noticeable in precision medicine, clinical diagnostics, and drug discovery. Compound screening procedures are optimized, medication responses are predicted, and molecular targets are identified using machine learning algorithms. AI improves pathology and diagnostic imaging techniques, allowing for earlier and more precise illness diagnosis. By automating repetitive and data-intensive processes, these programs enhance research results, facilitate regulatory compliance, and lower operating expenses.
The increasing amount of complicated biological data and the requirement for more effective tools to extract valuable insights are major factors driving this trend. Businesses in the life sciences are increasingly collaborating with suppliers of AI technology to create specialized solutions for research problems. AI-as-a-service models and cloud-based platforms further democratize access to sophisticated analytics, allowing even academic institutions and mid-sized businesses to take advantage of AI's promise without having to make large upfront infrastructure investments.
It is anticipated that the future of life science tools will be redefined by the confluence of AI with next-generation sequencing (NGS), CRISPR gene-editing techniques, and single-cell analysis. AI algorithms' function will change from being a tool for processing data to a strategic asset that spurs innovation as they grow more complex and interpretable. Businesses that invest in AI-powered life science technologies stand to benefit from quicker innovation cycles, more effective products, and better alignment with trends in customized healthcare. This change in technology emphasizes how crucial AI is to the expansion and change of the global life science tools market.
Expansion of the Biotechnology Sector
Over the past ten years, the biotechnology industry has grown significantly thanks to advancements in molecular diagnostics, genetic engineering, and biopharmaceuticals. Biotech businesses are essential to the advancement of agriculture, healthcare, and environmental sustainability on a global scale. Increased government funding, venture capital firm investments, and strategic partnerships with pharmaceutical corporations all contribute to this expansion. While developed markets continue to drive innovation, emerging economies are catching up quickly thanks to their more affordable research resources, highly qualified scientific workforce, and better regulatory frameworks.
Growing demand for cutting-edge healthcare solutions, infrastructure development, and supportive government policies is making emerging nations in Asia, the Pacific, and Latin America hotspots for biotech expansion. Through tax breaks, research funding, and public-private partnerships, nations like China, India, and Brazil encourage biotech innovation. This regional expansion increases the demand for life science technologies in cell biology, proteomics, and genomics. The need for state-of-the-art analytical and laboratory instruments is anticipated to increase dramatically as biotech companies in these areas continue to develop their R&D pipelines, setting up the market for long-term worldwide expansion.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Market Concentration & Characteristics
The market for the life science sector is highly innovative, propelled by quickening technical development, rising R&D expenditures, and rising demand for individualized medication. Research skills are changing as a result of emerging fields like proteomics, genomics, and AI-driven analytics. The creation of innovative tools and solutions is also being accelerated by partnerships among academic institutions, biotech companies, and healthcare providers.
The need to broaden product portfolios, gain access to cutting-edge technology, and fortify market positions is driving an increase in mergers and acquisitions in the life science sector. Businesses are strategically merging to increase their capacity for research, get economies of scale, and spur innovation. Increasing competition, the need for integrated solutions, and an emphasis on breaking into emerging markets with significant development potential are further factors driving this trend.
Regulatory frameworks have a greater and more impact on how the life science sector develops. Strict regulations guarantee product quality, safety, and efficacy, promoting public confidence and global market access. Regulatory agencies are also responding to scientific discoveries by expediting the approval procedures for novel treatments and technologies. This changing environment promotes investment, shortens time to market, and sustains industry growth in all parts of the world.
Rapid advances in biotechnology, diagnostics, and research tools are driving the life science industry's ongoing product expansion and tremendous pace. Businesses are expanding their product lines to satisfy the changing demands of data-driven research, molecular biology, and precision medicine. This expansion promotes rapid innovation and a wider market reach by improving competitive positioning and enabling customized solutions for the academic, pharmaceutical, and healthcare sectors.
To accelerate the growth of the global life science business, regional expansion is essential. Because of their extensive biotechnology and pharmaceutical R&D funding, solid research infrastructure, and encouraging regulatory regimes, North America and Europe are at the forefront. Established academic institutions, widespread use of cutting-edge technologies, and a significant concentration of important industry players all contribute to these regions' success in fostering innovation and establishing international standards for excellence in science and business.
Technology Insights
In 2024, the segment with the highest revenue share—33.94%—was cell biology technology. Cell biology technology's crucial role in vaccine development, regenerative medicine, cancer research, and medication discovery explains this. The segment's expansion has also been fueled by the rising need for sophisticated cell analysis technologies, such as flow cytometry and high-content screening. Furthermore, the range of applications for cell biology technology has increased due to increased funding for stem cell research and biologics development. Academic institutions and biopharmaceutical businesses continue to use these tools, resulting in steady revenue growth in international markets.
Because more people want personalized treatment, better next-generation sequencing, and lower costs for genetic analysis, the genomic technology market is expected to grow the fastest over the next few years. The use of genomic techniques in research and healthcare contexts is also being accelerated by growing applications in clinical diagnostics, uncommon diseases, cancer genomics, and gene therapy.
Product & Services Insights
With a 16.48% revenue share in 2024, the cell culture systems and 3D cell culture category led the market. The increase is ascribed to the growing need for physiologically realistic models in toxicology, cancer research, and drug discovery. Compared to conventional techniques, 3D cultures provide improved cellular connections and more precise biological reactions. Furthermore, increased spending on tissue engineering and regenerative medicine propels the use of cutting-edge cell culture technology in both clinical and research settings.
Over the course of the projection period, the next-generation sequencing segment is anticipated to grow at the fastest CAGR of 13.79% due to its rising applications in clinical diagnostics, oncology, and personalized medicine. Thanks to improvements in sequencing speed, accuracy, and affordability, NGS is now more widely available for use in healthcare and research contexts. Demand is further accelerated by its use in infectious disease monitoring, population genetics, and biomarker development, which establishes NGS as a major force behind market innovation.
End-use Insights
The healthcare segment held the largest life science market revenue share of 32.01% in 2024, driven by the growing use of advanced research tools in diagnostics, therapeutic development, and disease monitoring. Increased investment in precision medicine, biologics, and clinical research has significantly boosted demand for life science technologies in hospitals, laboratories, and pharmaceutical settings. Furthermore, the rising prevalence of chronic and genetic diseases has further accelerated the integration of innovative tools within the healthcare ecosystem.
The biopharmaceutical segment is expected to grow fastest throughout the forecast period. This is attributed to increasing demand for biologics, including monoclonal antibodies, cell and gene therapies, and vaccines. Advancements in bioprocessing technologies, coupled with rising investment in R&D, are driving innovation and productivity in biopharmaceutical manufacturing. Also, more people are getting chronic and rare diseases, and there is good support from regulations for new treatments, which is speeding up the use of life science tools in this area.
Competitive Scenario Insights
The market is highly competitive and characterized by rapid innovation, strategic collaborations, and continuous product development. Key players are focusing on expanding their portfolios to cater to the growing demand in genomics, proteomics, cell biology, and bioinformatics. Mergers and acquisitions remain a central strategy, enabling companies to strengthen market positions, gain access to cutting-edge technologies, and expand geographically. Furthermore, rising competition has led to increased investment in research and development to improve the precision, efficiency, and scalability of life science tools.
Technological differentiation is a significant factor driving market competition. Companies are prioritizing the integration of artificial intelligence, automation, and cloud-based platforms into their tools to offer more comprehensive and user-friendly solutions. The demand for multifunctional instruments to handle complex workflows in real time accelerates innovation. Furthermore, the shift toward personalized medicine and targeted therapeutics has encouraged tool manufacturers to develop solutions tailored to niche applications in genomics and molecular diagnostics.
The market features a mix of established global leaders and rapidly emerging players. Leading companies such as Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, and Illumina dominate through their expansive product lines, global presence, and strong customer bases. These firms continuously invest in R&D, partnerships, and acquisitions to maintain technological superiority. Meanwhile, emerging players, particularly from Asia Pacific and Europe, are gaining traction by introducing affordable, innovative solutions tailored to regional research needs. Startups focusing on niche technologies like CRISPR, single-cell analysis, and AI-driven platforms are also disrupting the market and attracting investor attention.
Competition is expected to intensify as companies race to align their portfolios with evolving research priorities, regulatory changes, and healthcare trends. Success in this market will increasingly depend on the ability to innovate rapidly, offer integrated solutions, and provide strong customer support. Market players that can effectively anticipate scientific and technological shifts while maintaining cost efficiency will likely lead in the next phase of industry growth.
Regional Insights
North America dominated the life science tools industry with the largest revenue share of 44.69% in 2024, driven by a strong presence of key market players, advanced research infrastructure, and substantial investment in biotechnology and pharmaceutical R&D. The region benefits from high adoption of cutting-edge technologies, robust funding from both government and private sectors, and a well-established regulatory framework supporting innovation. Moreover, growing demand for personalized medicine, rising healthcare expenditure, and the prevalence of chronic and genetic disorders have further fueled the need for advanced research tools, solidifying North America’s leadership in the global market.
U.S Life Science Tools Market Trends
The life science tools market in the U.S. is the largest in North America, primarily due to its advanced healthcare infrastructure and substantial investment in biomedical research. The presence of leading biotech firms and academic institutions further drives innovation and adoption.
Europe Life Science Tools Market Trends
The life science tools market in Europe is highly concentrated, supported by strong government funding, well-established research institutions, and a growing biopharmaceutical sector. Countries such as Germany, the UK, and France lead in adopting advanced technologies for genomics, proteomics, and cell biology research. The region also benefits from a collaborative ecosystem between academia, industry, and regulatory bodies, which fosters innovation. In addition, increasing focus on personalized medicine, rising healthcare expenditure, and supportive regulatory frameworks contribute to the market’s expansion. Europe’s emphasis on sustainability and digital health further strengthens its position in the evolving global life science tools landscape.
The UK life science tools market is experiencing strong growth, with robust government support, expanding biotech startups, and advanced research infrastructure. An increasing focus on genomics, precision medicine, and public-private partnerships is further accelerating market development.
The life science tools market in Germany is experiencing significant growth, driven by its strong pharmaceutical and biotechnology sectors, advanced manufacturing capabilities, and substantial R&D investment. Supportive government policies and a focus on innovation in diagnostics and therapeutics further accelerate market expansion.
Asia Pacific Life Science Tools Market Trends
The life science tools market in Asia Pacific is expected to grow significantly during the forecast period, owing to rising healthcare expenditures, expanding biotechnology and pharmaceutical industries, and increasing government initiatives to support life science research. Countries like China, India, South Korea, and Japan invest heavily in research infrastructure and foster innovation through public-private partnerships. The growing demand for advanced diagnostic tools, personalized medicine, and biologics is accelerating the adoption of life science technologies. Furthermore, a large patient population, improving regulatory frameworks, and the presence of skilled scientific talent are attracting global players to expand their operations in the region, driving robust market growth.
The China life science tools market is set to grow significantly, fueled by increased government investment in biotechnology, expanding pharmaceutical R&D, and a rapidly growing healthcare sector. The country focuses on innovation through strategic policies and funding for genomics, diagnostics, and drug discovery. Moreover, the rise of local biotech firms and partnerships with global players is accelerating technology adoption and market expansion.
The life science tools market in Japan is growing rapidly due to its strong emphasis on medical research, an aging population driving demand for advanced healthcare solutions, and robust government support for biotechnology innovation. The country's leadership in precision medicine, diagnostics, and regenerative therapies further contributes to increased adoption of cutting-edge tools for life sciences.
MEA Life Science Tools Market Trends
The life science tools market in the Middle East and Africa is projected to drive the demand for life science tools and grow considerably due to rising investments in healthcare infrastructure, increasing prevalence of chronic diseases, and growing interest in biomedical research. Governments across the region are prioritizing healthcare modernization and innovation through national strategies and public-private partnerships. In addition, expanding pharmaceutical and biotechnology sectors and establishing research centers and academic collaborations are accelerating the adoption of advanced life science technologies. The region’s improving regulatory landscape and focus on local manufacturing further support sustained market growth.
Kuwait's life science tools market is projected to grow steadily, driven by increasing investments in healthcare infrastructure, rising demand for advanced diagnostic technologies, and a growing focus on research and development. The country's commitment to enhancing its healthcare sector and adopting innovative solutions positions it as a significant player in the regional life science landscape.
Key Life Science Tools Company Insights
Key players operating in the market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling market growth.
Key Life Science Tools Companies
The following are the leading companies in the life science tools market. These companies collectively hold the largest market share and dictate industry trends.
- Agilent Technologies, Inc.
- Becton
- Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- Merck KGaA
- Shimadzu Corporation
- Hitachi, Ltd.
- Bruker Corporation
- Oxford Instruments plc
- Zeiss International
Recent Developments
-
In May 2025, Alamar Biosciences partnered with SciLifeLab to advance translational proteomics and accelerate biomarker discovery. The company aims to enhance disease understanding and improve diagnostics through high-sensitivity protein analysis and cutting-edge research collaboration.
-
In April 2025, Honeywell launched an AI-assisted automation platform designed for the life sciences manufacturing industry, introducing a revolutionary approach to workflow management aimed at enhancing operational efficiency and optimizing process performance.
-
In April 2025, Valted Seq launched SCADE, a revolutionary AI-powered genomics tool designed to accelerate breakthroughs in healthcare and life sciences. SCADE significantly outperforms generic models, including those from OpenAI and DeepSeek, by more than doubling their accuracy in solving challenges related to single-cell genomics.
Life Science Tools Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 184.28 billion |
|
Revenue forecast in 2030 |
USD 299.56 billion |
|
Growth rate |
CAGR of 10.21% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018-2023 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Product & service, technology, end-use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Switzerland; India; China; Japan; Australia; South Korea; Thailand; Singapore; Brazil; Argentina; Saudi Arabia; UAE; South Africa; Kuwait |
|
Key companies profiled |
Agilent Technologies, Inc.; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; Bio-Rad Laboratories, Inc.; Danaher Corporation; Illumina, Inc.; Thermo Fisher Scientific, Inc; QIAGEN N.V.; Merck KGaA; Shimadzu Corporation; Hitachi Ltd.; Bruker Corporation; Oxford Instruments plc; Zeiss International |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts’ working days) with purchase. The scope of the country, region, and segment can be expanded or altered. |
Global Life Science Tools Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the subsegments from 2018 to 2030. For this report, MIR has segmented the global life science tools market based on product & service, technology, end use, and regions
-
Product & Service Outlook (Revenue, USD Million, 2018-2030)
-
Cell Culture Systems & 3D Cell Culture
-
Instruments
-
Consumables
-
Cell & Tissue Culture Services
-
-
Liquid Chromatography
-
Instruments
-
Consumables
-
Services
-
-
Mass Spectrometry
-
Instruments
-
Consumables
-
Services
-
-
Flow Cytometry
-
Instruments
-
Consumables
-
Services
-
-
Cloning & Genome Engineering
-
Kits, Reagents, and Consumables
-
Services
-
-
Microscopy & Electron Microscopy
-
Instruments
-
Consumables
-
Services
-
-
Next Generation Sequencing
-
Instruments
-
Consumables
-
Services
-
-
PCR & qPCR
-
Instruments
-
Consumables
-
Services
-
-
Nucleic Acid Preparation
-
Instruments
-
Consumables
-
Services
-
-
Nucleic Acid Microarray
-
Instruments
-
Consumables
-
Services
-
-
Sanger Sequencing
-
Instruments
-
Consumables
-
Services
-
-
Transfection Devices & Gene Delivery Technologies
-
Equipment
-
Reagents
-
-
NMR
-
Instruments
-
Consumables
-
Services
-
-
Other Separation Technologies
-
Instruments
-
Consumables
-
Services
-
-
Other Products & Services
-
Antibodies
-
General Supplies
-
Others
-
Instruments
-
Consumables
-
Services
-
-
-
-
Technology Outlook (Revenue, USD Million, 2018-2030)
-
Genomic Technology
-
Proteomics Technology
-
Cell Biology Technology
-
Other Analytical & Sample Preparation Technology
-
Lab Supplies & Technologies
-
-
End-use Outlook (Revenue, USD Million, 2018-2030)
-
Government & Academic
-
Biopharmaceutical Company
-
Healthcare
-
Industrial Applications
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2018-2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
Switzerland
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Singapore
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy